Gain Therapeutics (NASDAQ: GANX) – Market Snapshot
- Last trade time: 11:57 AM Central Europe, Thursday 22 Oct 2026
- Closing price: USD 1.19
- Price movement (24 h): Flat, 0 %
- Shares outstanding: 43.6 million
- Market capitalization: USD 51.9 million
- Volume (last 24 h): USD 725.3 k
- Year‑to‑date performance: Down 38.97 % from the previous month‑end
- 200‑day simple moving average: USD 1.90
- 52‑week range:
- High: USD 4.34 (11 Dec 2025)
- Low: USD 1.15 (21 Oct 2026)
Recent Activity of Peer Companies
| Symbol | Current Price | % Change (24 h) | Market Capitalization | Key Update |
|---|---|---|---|---|
| CITR (Citrotech) | USD 2.64 | +1.54 % | USD 60.7 million | Filed SEC update confirming name change and corporate structure; effective 20 Oct 2026. |
| HYFT (Mindwalk) | USD 1.27 | –1.55 % | USD 60.8 million | Released white paper on LensAI immunogenicity screening; claims high‑throughput antibody analysis at reduced cost on AMD‑based EC2 instances. |
| NFE (New Fortress Energy) | USD 3.76 | +1.08 % | USD 60.7 million | – |
| CVU (Cpi Aerostructures) | USD 4.70 | –0.84 % | USD 62.3 million | P/E ratio: 18.69. |
| XBIT (Xbiotech) | USD 1.99 | –1.49 % | USD 61.6 million | – |
Company Overview
Gain Therapeutics, Inc. is a healthcare company headquartered in Bethesda, United States, listed on Nasdaq. The firm focuses on drug discovery through a proprietary platform that identifies and optimizes allosteric binding sites previously untargeted. This approach aims to develop new treatment options for conditions associated with protein misfolding. Further information is available on the company’s website: www.gaintherapeutics.com .
